



vTv Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

December 2, 2019

HIGH POINT, N.C., Dec. 02, 2019 (GLOBE NEWSWIRE) -- [vTv Therapeutics Inc.](#) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and Alzheimer's disease, today announced that it is scheduled to present a general company update at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 10:50 a.m. Eastern Time in New York City. Company management will also be meeting with members of the investment community during one-on-one meetings at the conference.

A live webcast of the presentation can be accessed [here](#) and will be accessible for 30 days following the presentation at www.vtvtherapeutics.com.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes, Alzheimer's disease, and inflammatory disorders. vTv's development partners are pursuing additional indications in type 2 diabetes, COPD, and genetic mitochondrial diseases.

Contacts

Investors:

vTv Therapeutics Inc.

IR@vtvtherapeutics.com

or

Media:

Glenn Silver

Lazar FINN Partners

646-871-8485

gsilver@lazarpartners.com



Source: vTv Therapeutics Inc.